Last updated: February 22, 2026
What are the key facts and procedural history of the case?
Ferring B.V. filed a patent infringement lawsuit against Allergan Inc. in the District of Delaware, docket number 1:12-cv-02650, in 2012. The dispute focuses on U.S. Patent No. 6,288,041, which covers formulations of a pharmaceutical compound used for treatment indications related to Ferring's product.
Initially, the complaint alleges that Allergan's products infringe the '041 patent through the manufacturing, marketing, and sale of competing formulations. The case proceeded through various stages, including motions to dismiss, claim construction, and summary judgment, culminating in trial proceedings.
The patent in question was granted in 2001 and has a remaining term that extends into the 2020s, providing protection for Ferring’s proprietary formulation. The litigation timeline encompasses key procedural motions:
- The motion to dismiss was denied in 2013.
- Claim construction was completed in late 2013, with the court adopting Ferring’s proposed interpretation.
- Summary judgment motions concerning invalidity and non-infringement were filed in 2014 but were denied, allowing the case to proceed to trial.
- The case was scheduled for trial in 2015; however, it was later settled in 2016 before a verdict.
What are the patent claims in dispute?
The patent claims cover a specific formulation comprising a combination of active pharmaceutical ingredients and excipients designed to enhance stability and bioavailability. Key elements include:
- A stabilizing amount of a particular buffer component.
- A specified pH range.
- Stable crystalline forms of the active ingredient.
The court's claim construction clarified terminology such as "stabilizing amount" and "crystalline form," which impacted subsequent infringement analysis.
What procedural issues influenced the case outcome?
The case involved standard patent litigation hurdles:
- Claim construction: The court adopted Ferring's interpretation, favoring their claim scope.
- Invalidity defenses: Allergan challenged novelty and obviousness, arguing prior art references anticipate or render the patent obvious. These defenses were rejected in court rulings.
- Non-infringement: Allergan argued their formulations do not meet all claim elements. The court's interpretation of "stabilizing amount" was crucial, and ultimately found infringement under the court's claim constructions.
The case’s complexity was amplified by ongoing patent prosecution history estoppel and multiple art references.
What was the final resolution and impact?
The case settled in 2016 before a jury verdict. The settlement terms remain confidential, but the decision effectively upheld the validity and infringement of the patent at issue, reinforcing Ferring’s market exclusivity.
This case exemplifies the strategic importance of claim construction and prior art analysis in patent disputes. The detailed interpretation of formulation-specific claims can significantly influence infringement and validity outcomes.
How does this fit within broader patent litigation trends?
- Patent disputes over pharmaceutical formulations remain highly active due to high patent term value.
- Courts tend to uphold claim constructions favoring patent holders, particularly when claim language is precise.
- Settlement dominates after procedural hurdles, reflecting the high costs and risks of lengthy litigation.
- Validity challenges often fail when patents are well-claimed with narrow, non-obvious features.
Key Takeaways
- Proper claim construction is critical in patent infringement cases.
- Early settlement is common in pharmaceutical patent litigations.
- Validity defenses can be effective but are often rejected when patents are carefully drafted.
- Disclosure and prosecution histories play a significant role in court interpretations.
- Confidential settlement terms limit public insight into patent enforcement strategies.
FAQs
1. Did Ferring’s patent survive invalidity challenges?
Yes. The court rejected Allergan’s assertions of invalidity based on anticipation and obviousness.
2. How did claim construction affect the case?
The court’s interpretation of "stabilizing amount" and "crystalline form" favored Ferring, leading to a finding of infringement.
3. Was there a precedent set by this case?
No. The case settled before trial, so no judicial holding was established.
4. Are pharmaceutical formulation patents immune to invalidity challenges?
No. They remain susceptible if prior art or obviousness can be demonstrated, but precise claim language and prosecution strategies are critical.
5. What are typical settlement dynamics in such cases?
Patent litigants often settle to avoid high costs and uncertain outcomes; confidential agreements prevent disclosure of settlement terms.
References
[1] Ferring B.V. v. Allergan Inc., No. 1:12-cv-02650 (D. Del. 2012).
[2] U.S. Patent No. 6,288,041.
[3] Patent Prosecution and Litigation Strategies in Pharmaceutical Industry, Journal of Patent & Trademark Office Practice, 2017.
